SUZHOU, China, March 13, 2026 /PRNewswire/ — Alphamab Oncology (stock code: 9966.HK) announced that the Investigational New Drug (IND) application for JSKN021, an independently developed innovative dual payload bispecific antibody-drug conjugate (ADC) targeting EGFR and HER3, has been officially accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). The Company plans to initiate a clinical study of JSKN021 for the treatment of advanced malignant solid tumors. JSKN021 is a "2-in-1" dual payload bispecific ADC targeting EGFR and HER3. By leveraging glycan-specific conjugation technology, it precisely and quantitatively links two different cytotoxic payloads to the antibody's…